Pliquet, Elodie http://orcid.org/0000-0003-4242-8569
Ruffie, Claude
Escande, Marie
Thalmensi, Jessie
Najburg, Valérie
Combredet, Chantal
Bestetti, Thomas
Julithe, Marion
Liard, Christelle
Huet, Thierry http://orcid.org/0000-0001-9842-591X
Wain-Hobson, Simon http://orcid.org/0000-0002-6406-3858
Tangy, Frédéric http://orcid.org/0000-0002-5937-5654
Langlade-Demoyen, Pierre
Funding for this research was provided by:
Association Nationale de la Recherche et de la Technologie (2012/0152)
Article History
Received: 2 March 2018
Accepted: 1 November 2018
First Online: 17 January 2019
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: All protocols have been submitted and approved by the Pasteur Institute office of laboratory animal care CETEA no. 89 under the references 2013-0026 on February 01st, 2013 and 2014-0061 on October 07th, 2015 and by French Committee for Hygiene, Safety and Working Conditions (CHSCT) under the reference 07.157 on April 10th, 2007 and 16.0013 on January 8th, 2016. All in vivo experiments were conducted in strict accordance with good animal practice and complied with local animal experimentation and ethics committee guidelines of the Pasteur Institute (agreement no. 75-15-01 delivered on the 06th September 2013 and no. A75-15-01-1 on 18th August 2014) and Directive 2010/63/EU on the harmonization of laws, regulations and administrative provisions relating to the protection of animals.
: IFNAR/CD46 (IFN-α/βR<sup>−/−</sup> CD46<sup>+/−</sup>) mouse strain used for immunization experiments was generated by Frédéric Tangy’s team by cross-breeding and backcross between FVB/CD46<sup>+/−</sup> mice (gift from F. Grosveld, Erasmus University, Rotterdam, The Netherlands) and 129sv IFN-α/βR<sup>−/−</sup> mice which lack the type I IFN receptor (gift from M. Aguet, Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland). HHD/IFNAR/CD46 (HHD<sup>+/+</sup> CD46<sup>+/−</sup> IFN-α/βR<sup>−/−</sup>) mouse strain was generated by Frédéric Tangy’s team by cross-breeding and backcross between HHD mice (human β2m–HLA-A2.1 α1α2-H-2D<sup>b</sup>α3-transmembrane and H-2Db<sup>−/−</sup>β2mb<sup>−/−</sup> double knockout; mice generated at Pasteur Institute by François Lemonnier) and IFNAR/CD46 mice.
: HEK-293-T7-MV cell line was produced, provided and patented by Frédéric Tangy and the Institut Pasteur. Vero cells were provided by the American Type Culture Collection (ATCC<sup>®</sup>) under reference number CCL-81™.